# Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)

> **NCT00807053** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 480 (actual)

## Conditions studied

- Rhinitis, Allergic, Seasonal

## Interventions

- **DRUG:** Ciclesonide HFA
- **DRUG:** Ciclesonide HFA
- **DRUG:** Ciclesonide HFA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00807053
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2007-06
- **Final completion:** 2007-07
- **Target enrollment:** 480 (ACTUAL)
- **Last updated:** 2016-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00807053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00807053, "Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00807053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*